TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04091022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solaraze and Vaniqa
Description: Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solaraze and Vaniqa
Description: Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months
Study: NCT04980508

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: corpus cavernosum electromyography
Description: Cc-EMG was performed by using the cc-EMG module of Ellipse 4 device (Andromeda, Germany), which comprises of a 2-channel electromyography amplifier with a row sampling rate of 16 kHz, filtered sampling rate of 166.67 Hz and a band width of 0.5-30 Hz with the speed of the thermo-writer paper set at 5 mm/s. Measurements of the electrical activity of the corpus cavernosum (EACC) were done for 10 minutes using coaxial needle electrodes during the flaccid state and after intracavernous papaverine (60 mg) injection.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: corpus cavernosum electromyography
Description: Cc-EMG was performed by using the cc-EMG module of Ellipse 4 device (Andromeda, Germany), which comprises of a 2-channel electromyography amplifier with a row sampling rate of 16 kHz, filtered sampling rate of 166.67 Hz and a band width of 0.5-30 Hz with the speed of the thermo-writer paper set at 5 mm/s. Measurements of the electrical activity of the corpus cavernosum (EACC) were done for 10 minutes using coaxial needle electrodes during the flaccid state and after intracavernous papaverine (60 mg) injection.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: corpus cavernosum electromyography
Description: Cc-EMG was performed by using the cc-EMG module of Ellipse 4 device (Andromeda, Germany), which comprises of a 2-channel electromyography amplifier with a row sampling rate of 16 kHz, filtered sampling rate of 166.67 Hz and a band width of 0.5-30 Hz with the speed of the thermo-writer paper set at 5 mm/s. Measurements of the electrical activity of the corpus cavernosum (EACC) were done for 10 minutes using coaxial needle electrodes during the flaccid state and after intracavernous papaverine (60 mg) injection.
Study: NCT05245409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustment using an activator
Description: Chiropractic adjustment using an activator
Study: NCT04283981

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group without use of VSP
Description: The control group will include patients that undergo mandibular reconstruction via open reduction internal fixation (intraoral or extraoral approach) in standard fashion (without virtual surgical planning assistance and occlusal splint)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Group with use of VSP
Description: The treatment group corresponds to patients undergoing mandibular reconstruction via open reduction internal fixation (intraoral or extraoral approach) utilizing virtual surgical planning via 3D Systems, bite registration and fabrication of occlusal splint via intraoral digital scanner, and mandibular hardware
Study: NCT06101953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management
Description: It spanned 12 weeks, with three hours per week (comprising two hours of theoretical content and one hour of practical application) and employed diverse teaching methods, including lectures, interactive learning, research, fieldwork, hands-on practice, and question-answer sessions. The primary objective of this course was to enhance students' awareness of stress by helping them identify its sources, symptoms, and effects. Also interception and resilience. Furthermore, it aimed to teach students how to assess stress and apply stress-management techniques effectively in their daily lives.
Study: NCT05302934

Intervention type: DEVICE
Intervention: Pheno4U
Description: Total Knee Arthroplasty represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or other indications resulting in joint destruction. In general, Implantation of a total knee prosthesis improves the quality of life through pain alleviation, deformity correction, joint stabilization, and/or functional range of motion (ROM) through restoration of normal knee kinematics and functionality
Study: NCT06164301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elemental amino-acids
Description: mono peptide oral protein formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Elemental amino-acids
Description: mono peptide oral protein formula
Study: NCT05207735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: * Sintilizumab, 200 mg, intravenous infusion, a treatment cycle every 3 weeks, administration on the first day of each cycle, 6 cycles.~* Capecitabine: 1250 mg/m2, orally, twice a day, 1-14 days, one treatment cycle every three weeks, 8 cycles.
Study: NCT05276557

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PyloPlus Urea Breath Test System
Description: System containing a kit containing 13C urea and breath collection bags, and an analyzer to test breath samples pre and post 13C ingestion.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stool Antigen Test
Description: An antigen test performed via a laboratory to test patients' stool for H. pylori
Study: NCT05196581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dispersible NaCl powder 10 sessions
Description: Dispersible NaCl powder 10 sessions
Study: NCT06418802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: frequency
Description: frequency parameters of STN-DBS (60,100, and 130HZ)
Study: NCT05196581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dispersible NaCl powder 5 sessions
Description: Dispersible NaCl powder 5 sessions
Study: NCT05897203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAZCOV
Description: Herbal Syrup

Intervention type: DRUG
Group type: OTHER
Intervention: TAZCOV
Description: Herbal Syrup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vidicine
Description: Herbal Syrup

Intervention type: DRUG
Group type: OTHER
Intervention: Vidicine
Description: Herbal Syrup
Study: NCT05969496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib is a potent oral, vascular endothelial growth factor, c-kit and platelet derived growth factor inhibitor.
Study: NCT06470802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Familiar voice
Description: The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nature sounds
Description: The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval
Study: NCT05490979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contemplative dyad meditation
Description: Participants take part in a 3-hour group meditation training led by a professional meditation teacher. They receive detailed instructions and also practice contemplative dyad meditation for at least 30 minutes with another participant. During the 2 weeks following the training, participants meet in supervised group settings to practice the meditation method with alternating partners for up to 6 times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fast friends
Description: During 2 weeks, participants meet in supervised group settings to practice the 'fast friends' exercise with alternating partners for up to 6 times.
Study: NCT05737043

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: prenatal diagnose
Description: we will do a fetal echo in pregnant women with polyhidramnios

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: prenatal diagnose
Description: we will do a fetal echo in pregnant women with polyhidramnios
Study: NCT06335992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise regime
Description: Exercise
Study: NCT05969496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a type of immunotherapy. It stimulates the body's immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
Study: NCT06474715

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arms
Description: The intervention includes a task-based interaction (volunteer activities) where cognitive demand is low and interactional roles are clear. The focus is on the task, rather than developing relationships, reducing the pressure of interaction. As the volunteer activities continue, they also offer the opportunity for group members to enhance empathy, another salient component of cross-group relational development. Mediated interaction supports new relational development through a disinhibiting effect, lowering inhibitions and increasing comfort and disclosure
Study: NCT05717426

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open chain exercises
Description: An open chain exercise is one that allows the furthest part of the chain to move freely. For example, picking up a glass of water is an open-chain exercise. The hand affects the elbow and the shoulder as it is not fixed in place. However, it does not effect the rest of your body.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed kinetic chain exercises
Description: Closed Kinetic Chain (CKC) exercises or closed chain exercises are exercises or movements where the distal aspect of the extremity is fixed to an object that is stationary.
Study: NCT06249503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: The patients hand will be facing upwards and slightly extended, the Median nerve will be identified at the inlet of the carpal tunnel. Ultrasound guided injection will be done with the use of the ulnar in-plane technique. with a 25-gage needle will be introduced from the ulnar side of the wrist between carpal tunnel and median nerve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: The patients hand will be facing upwards and slightly extended, the Median nerve will be identified at the inlet of the carpal tunnel. Ultrasound guided injection will be done with the use of the ulnar in-plane technique. with a 25-gage needle will be introduced from the ulnar side of the wrist between carpal tunnel and median nerve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: The patients hand will be facing upwards and slightly extended, the Median nerve will be identified at the inlet of the carpal tunnel. Ultrasound guided injection will be done with the use of the ulnar in-plane technique. with a 25-gage needle will be introduced from the ulnar side of the wrist between carpal tunnel and median nerve.
Study: NCT05172167

Intervention type: DIAGNOSTIC_TEST
Intervention: Levels of IgG and IgM SARS-CoV-2 antibodies blood test.
Description: 0,1,2 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Levels of IgG and IgM SARS-CoV-2 antibodies blood test.
Description: 0,1,2 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Levels of IgG and IgM SARS-CoV-2 antibodies blood test.
Description: 0,1,2 months

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR SARS-CoV-2 nasopharyngeal swab
Description: 0,1,2 months

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR SARS-CoV-2 nasopharyngeal swab
Description: 0,1,2 months

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR SARS-CoV-2 nasopharyngeal swab
Description: 0,1,2 months
Study: NCT05114915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound docetaxel
Description: Albumin-bound docetaxel by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound docetaxel
Description: Albumin-bound docetaxel by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound docetaxel
Description: Albumin-bound docetaxel by intravenous infusion
Study: NCT06062225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kamikawa
Description: Kamikawa reconstruction after proximal gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STJI
Description: Single-Tract Jejunal Interposition(STJI) reconstruction after proximal gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOFY
Description: SOFY reconstruction after proximal gastrectomy
Study: NCT04450654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamunex-C
Description: Gamunex-C IVIG will be given at week 0 and week 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin
Description: 1% albumin solution dosed at equivalent volume to the corresponding weight-based Gamunex-C IVIG dose will be given at week 0 and week 4
Study: NCT06265766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS
Description: 10 sessions of cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: cTBS
Description: 10 sessions of cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.
Study: NCT05978284

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG006
Description: ZG006 will be administered as an intravenous (IV) infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG006
Description: ZG006 will be administered as an intravenous (IV) infusion.
Study: NCT05206695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-condition Pathway Intervention
Description: See Experimental/Arm 1 description
Study: NCT05211154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium 50Mg/Pkt Oral Pwdr
Description: Treatment for an acute, moderate to severe migraine attack

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimegepant 75 MG
Description: Treatment for an acute, moderate to severe migraine attack
Study: NCT04907695

Intervention type: DEVICE
Intervention: I View Video Laryngoscope https://www.intersurgical.com/content/files/108253/-1977057700
Description: All intubations will be performed at the direction of the attending clinician. The decision to intubate is based purely on clinical factors by the primary team. The decision to use VL device will be at the direction of the clinical team. No patient will be recruited specific for this procedure.
Study: NCT06052150

Intervention type: PROCEDURE
Intervention: Dental exam and periodontal cleaning if needed
Description: Dental exam and periodontal cleaning if needed
Study: NCT06474715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arms
Description: The intervention includes a task-based interaction (volunteer activities) where cognitive demand is low and interactional roles are clear. The focus is on the task, rather than developing relationships, reducing the pressure of interaction. As the volunteer activities continue, they also offer the opportunity for group members to enhance empathy, another salient component of cross-group relational development. Mediated interaction supports new relational development through a disinhibiting effect, lowering inhibitions and increasing comfort and disclosure
Study: NCT05323084

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement
Description: 1 week of each intervention at bedtime with a 2-week washout period in between interventions

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement
Description: 1 week of each intervention at bedtime with a 2-week washout period in between interventions
Study: NCT05756153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH925
Description: GFH925 tablets administered orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab administered intravenously Q2W.
Study: NCT04695496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta bust stimulating
Description: Theta burst stimulation with Magstim super rapid 2, over SMA. 3 section per day, for 5 days, total 15 sections.
Study: NCT06093789

Intervention type: OTHER
Intervention: PBQ-S1
Description: All patients will fill out Personality Belief Scale-Short Form (PBQ-S1) and Beck Anxiety Scale one day before the procedure and they will be registered.
Study: NCT06651619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Prescribed amount of bottled water the evening prior and 2 hours prior to team practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydration Education
Description: 30-60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydration Education
Description: 30-60 minutes
Study: NCT05419375

Intervention type: OTHER
Group type: OTHER
Intervention: Screening platform
Description: The screening platform will be used to determine biomarker eligibility for a linked Roche study based on tissue-based testing.
Study: NCT06245356

Intervention type: DRUG
Group type: OTHER
Intervention: Lonsurf
Description: Trifluridine/tipiracil orally 35 mg/m²/dose (D1-D5 twice daily, D1=D15)

Intervention type: DRUG
Group type: OTHER
Intervention: Lonsurf
Description: Trifluridine/tipiracil orally 35 mg/m²/dose (D1-D5 twice daily, D1=D15)

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Oxaliplatin intravenous injection 85 mg/m² every 2 weeks (D1=D15)

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Oxaliplatin intravenous injection 85 mg/m² every 2 weeks (D1=D15)

Intervention type: DRUG
Group type: OTHER
Intervention: Panitumumab
Description: Panitumumab intravenous injection 6 mg/kg (D1=D15)

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab intravenous injection 5 mg/kg (D1=D15)

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab
Description: Trastuzumab intravenous injection 4 mg/kg (D1=D15)

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Nivolumab intravenous injection 240 mg (D1=D15)
Study: NCT06415838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation
Description: A five-session brief behavioral activation treatment delivered face-to-face in the participants' home.~Session outline:~Session 1: Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log~Session 2: Discussion of life goals and values; planning of activities aligned with life goals and values for coming week~Session 3: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 4: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for the coming week; instructing the participant to independently continue to plan activities for the coming month.~Session 5: Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned with life goals and values; creating a maintenance plan.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care as Usual
Description: Care as Usual provided by primary care and/or municipal care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual
Description: Care as Usual provided by primary care and/or municipal care.
Study: NCT05883540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lysergic Acid Diethylamide Tartrate
Description: 25 μg p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide Tartrate
Description: 100 or 200 μg p.o.
Study: NCT06127056

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Definition Transcranial Alternating Current Stimulation (HD-tACS)
Description: tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham High-Definition Transcranial Alternating Current Stimulation (HD-tACS)
Description: In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 20-minute intervention.
Study: NCT05987397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idebenone 30 mg for 14 days
Description: The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idebenone 30 mg for 3 months
Description: The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.